TriSalus Life Sciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, covering the company's financial condition and results of operations for the third quarter.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $41,057 thousand as of September 30, 2026, up from $20,439 thousand at December 31, 2025.
  • Total assets: Total assets were $57,562 thousand at September 30, 2026, compared with $35,331 thousand at December 31, 2025.
  • Accounts receivable: Net accounts receivable were $6,126 thousand, with an allowance of $38 thousand, as of September 30, 2026.
  • Inventory: Inventory, net, was $4,638 thousand at September 30, 2026, rising from $3,077 thousand at December 31, 2025.
  • Shares outstanding: The registrant reported 61,699,034 shares of common stock outstanding as of November 6, 2026.
  • Trade payables: Trade payables were $4,231 thousand at September 30, 2026, compared with $3,002 thousand at December 31, 2025.

TriSalus Life Sciences Balance Sheet Changes Through September 30, 2026

According to the filing, TriSalus Life Sciences, Inc. (NASDAQ:TLSI), a Delaware-incorporated company headquartered in Westminster, Colorado, submitted its quarterly report covering the period ended September 30, 2026. The company is classified as a non-accelerated filer and a smaller reporting company, and confirmed it is not a shell company.

The condensed consolidated balance sheet disclosed in the filing shows total current assets of $54,897 thousand at September 30, 2026, compared with $32,244 thousand at December 31, 2025. The increase was driven primarily by the rise in cash and cash equivalents from $20,439 thousand to $41,057 thousand. Prepaid expenses also increased, reaching $3,076 thousand from $2,170 thousand over the same period. Property and equipment, net, was reported at $1,830 thousand, and right-of-use assets stood at $766 thousand as of the quarter-end date.

On the liabilities side, the filing reported accrued liabilities of $8,393 thousand and short-term lease liabilities of $277 thousand as of September 30, 2026. The company also disclosed that it has a history of operating losses and expects "significant expenses and continuing losses for the foreseeable future," characterizations the company itself made in its forward-looking statements section. The filing noted these forward-looking statements are subject to the company's cautionary language and numerous risks, including the ability to raise future financing and service indebtedness. The company's common stock and warrants are both listed on the Nasdaq Global Market, with the warrants exercisable for one share of common stock at an exercise price of $11.50 per share.

What Was Disclosed

TriSalus Life Sciences filed a 10-Q for Q3 2026 reporting a balance sheet as of September 30, 2026, showing total assets of $57,562 thousand, cash of $41,057 thousand, and 61,699,034 shares outstanding as of November 6, 2026.